FDA Bars New Patients From Avandia Study
The U.S. Food and Drug Administration is blocking new patients from taking part in a safety trial of GlaxoSmithKline PLC's diabetes treatment Avandia as regulators decide whether to keep the drug...To view the full article, register now.
Already a subscriber? Click here to view full article